Compound class:
Synthetic organic
Comment: This compound is a selective inhibitor of mitogen-activated protein kinase 10 (MAPK10, JNK3) [1]. It can cross the blood-brain barrier. MAPK10 (c-Jun N-terminal kinase 3, JNK3) activity has been linked to the development of neurodegenerative diseases like Parkinson's disease (PD). A selective inhibitor would be predicted to mitigate JNK3-mediated pathology, and offer potential as a PD therapeutic. Compound 25c was designed to test this hypothesis.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Shuai W, Bu F, Zhu Y, Wu Y, Xiao H, Pan X, Zhang J, Sun Q, Wang G, Ouyang L. (2023)
Discovery of Novel Indazole Chemotypes as Isoform-Selective JNK3 Inhibitors for the Treatment of Parkinson's Disease. J Med Chem, 66 (2): 1273-1300. [PMID:36649216] |